Benefit of early treatment in inflammatory polyarthritis patients with anti–cyclic citrullinated peptide antibodies versus those without antibodies

Eitemau Tebyg

• Association of a rheumatoid arthritis susceptibility variant at the CCL21 locus with premature mortality in inflammatory polyarthritis patients
  gan: Farragher, Tracey M, et al.
  Cyhoeddwyd: (2010)
• Long-term stability of anti-cyclic citrullinated peptide antibody status in patients with early inflammatory polyarthritis
  gan: Burr, Marian L, et al.
  Cyhoeddwyd: (2012)
• Association of Functional Outcome With Both Personal- and Area-Level Socioeconomic Inequalities in Patients With Inflammatory Polyarthritis
  gan: Harrison, Mark J, et al.
  Cyhoeddwyd: (2009)
• The role of rheumatoid arthritis genetic susceptibility markers in the prediction of erosive disease in patients with early inflammatory polyarthritis: results from the Norfolk Arthritis Register
  gan: Plant, Darren, et al.
  Cyhoeddwyd: (2011)
• Early treatment with, and time receiving, first disease-modifying antirheumatic drug predicts long-term function in patients with inflammatory polyarthritis
  gan: Farragher, Tracey M, et al.
  Cyhoeddwyd: (2009)